Kedrion Biopharma
Carla Scali has extensive experience in pharmacology and toxicology, currently serving as Preclinical Pharmacology & Toxicology Manager at Kedrion Biopharma since November 2015. Prior to this role, Carla held the titles of Principal Scientist - Group Leader in the In vivo Pharmacology Unit and Senior Scientist at Siena Biotech from July 2003 to June 2015. Additionally, Carla worked at the University of Florence from 1996 to June 2003 as a Research Associate and Post-doc fellow. Carla Scali's academic credentials include a Ph.D. in Pharmacology and Toxicology, a Post-Laurea School of Specialization in Pharmacology, and a Bachelor of Laws in Biological Science, all obtained from the Università degli Studi di Firenze, along with a post-graduate course focused on laboratory animal welfare and experimental procedures.
This person is not in the org chart
This person is not in any teams
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.